Search Results

EdiGene, Inc. announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass.

EdiGene, Inc. announced an oral presentation on the preclinical proof-of-concept (POC) data in non-human primate (NHP) model, including NHP disease model, for LEAPERTM 2.0-based in vivo RNA editing therapies at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) to be held on May 16-20, 2023 in Los Angeles, California.

EdiGene, Inc. and Neukio Biotherapeutics announced an R&D collaboration to develop next-generation immune cell therapies.

EdiGene, Inc. announced it will present preliminary safety and efficacy results for ET-01, its investigational gene-editing therapy for transfusion dependent β-thalassemia at the 64th American Society of Hematology Annual Meeting and Exposition on December 10-13, 2022 in New Orleans, Louisiana.

EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it had completed the last patient dosing in Phase I clinical trial of ET-01, its investigational gene-editing hematopoietic stem cell therapy for transfusion dependent β-thalassemia.

EdiGene, Inc. said it has entered into a research collaboration with Peking University Cancer Hospital to understand gene mutation frequency and clinicopathologic features of patients with advanced colorectal cancer in China.

EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies

EdiGene, Inc. entered a non-exclusive, worldwide license agreement with Boston Children’s Hospital for intellectual property related to methods and compositions for increasing fetal hemoglobin levels by disrupting BCL11A expression at the genomic level to treat hemoglobinopathies.

EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and HSC Transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

EdiGene, Inc. announced a research and development collaboration with Haihe Laboratory of Cell Ecosystem to develop hematopoietic stem cell regenerative therapies and platform technology by combining resources and expertise from both sides.